Abstract. The objective of these studies was to examine the murine pharmacokinetics, pharmacodynamics and metabolism of (3-(1H-indol-2-yl)phenyl)(1H-indol-2-yl)methanone (Indole 15), a novel tubulin inhibitor for the treatment of cancer. We developed HPLC and LC/MS/MS assays to quantitate Indole 15 and characterize its metabolites in vivo. Pharmacokinetic studies were performed after intravenous (IV), oral (PO) and subcutaneous (SC) administration of 10 mg/kg doses to male ICR mice. Urine and fecal samples were also collected over a 72-h period to identify metabolites. Pharmacodynamic studies were conducted by monitoring the tumor size change during a period of two weeks in PC-3 tumor bearing mice after daily IV administration of Indole 15 at doses of 0, 10, 50, 100 and 150 mg/kg. The pooled plasma concentration data after administration via different dose routes was simultaneously fitted by a two-compartmental model. Indole 15 was moderately well absorbed after PO and SC administration, with a bioavailable fraction of 0.27 and 0.72, respectively. The steady state volume distribution (V ss ) and clearance (CL) were estimated to be 7.0 l/kg and 4.36 l/h/kg, respectively. The mean data of PC-3 tumor growth in mice was fitted well by a transduction model using fixed plasma pharmacokinetics as a driving function. Analysis of the metabolites in mice indicated that the compound undergoes extensive oxidative metabolism with subsequent sulfation. These studies demonstrate that favorable pharmacokinetic and pharmacodynamic properties of Indole 15 offer hope for achieving pharmacological activity in early clinical trials.
Introduction
Microtubule-interacting drugs are important agents in cancer chemotherapy. Such drugs are commonly classified into two major categories: microtubule-stabilizing (e.g., taxanes) and microtubule-destabilizing agents (e.g., vinca alkaloids and colchicine). The potency, efficacy and widespread clinical use of these agents in a variety of cancers stand testament to the importance of tubulin and its role in cancer growth. Unfortunately, these drugs also share a common mechanism of drug resistance, namely P-glycoprotein or ATP binding cassette (ABC) transporter protein-mediated drug efflux, which limits their efficacy in many tumors. Therefore, new anticancer drugs that can overcome or circumvent the multidrug resistance represent an important field in drug discovery.
We recently reported promising in vitro and in vivo anticancer activity of a novel bis-indole agent [Indole 15; (3-(1H-indol-2-yl)phenyl)(1H-indol-2-yl)methanone] (1). This novel agent inhibits tubulin polymerization and arrests the cell cycle in G 2 -M phase (1) . It exhibits broad antitumor activity in a variety of cancer cells with IC 50 values ranging from 34-162 nM and retained its potent anticancer activity in cancer cell lines that overexpress P-glycoprotein, multidrug resistance associated proteins (MRP) and breast cancer-resistance protein (BCRP). Indole 15 also demonstrated the ability to inhibit PC-3 tumor xenograft growth as well as docetaxel and vinblastine, identifying it as a novel chemotherapeutic agent that can overcome taxane-resistant cancer induced by multidrug resistance.
Herein, we report the in vivo pharmacokinetics, pharmacodynamics and metabolism of Indole 15 in mice. Characterization of the pharmacokinetics, pharmacodynamics and metabolic profile of Indole 15 provided us with a better understanding of the factors affecting the in vivo efficacy of this chemical scaffold to direct future structure modification (1, 2) .
Materials and methods
Chemicals and reagents. (3-(1H-indol-2-yl)phenyl)(1H-indol-2-yl)methanone (Indole 15) and its internal standard ( Fig. 1) were synthesized and characterized in our laboratories as previously described (1) . The purities of synthesized compounds were confirmed by NMR, elemental analysis and mass spectrometry. At each time point, three to four mice were euthanized by CO 2 inhalation and blood samples (up to 600 µl each) were taken from the posterior vena cava. Blood samples were immediately centrifuged at 3,000 x g for 10 min. Two hundred microliters of plasma from each sample was transferred to a clean plastic tube and stored at -80˚C until analysis.
Sample preparation for HPLC-UV analysis in mouse pharmacokinetics.
A 100 µl aliquot of each plasma sample was spiked with 10 µl of an internal standard (a structural analog of Indole 15, 7.5 µg/ml final concentration) and mixed well with 1 ml of acetonitrile. After centrifugation at 12,000 x g, 4˚C for 5 min, the supernatant was collected and evaporated. The residues were reconstituted in 150 µl of mobile phase and an aliquot of 100 µl was used for HPLC analysis.
HPLC-UV analysis. Mean values of tumor size were modeled by a transduction model described previously (4, 5) with the assumption that the effect of drug is to shunt cycling cells into a successive series of compartments after which the cells are dead (6). A schematic representation of the model is shown in Fig. 2 (6) .
The variance models for both pharmacokinetics and pharmacodynamics were defined as the followings:
where σ 1 and σ 2 are the variance parameters, and Ŷ represents model predicted value of drug concentration or tumor size.
The goodness of fit was assessed by model convergence, visual inspection, precision of the parameter estimates, Akaike Information Criteria (AIC), Schwarz Criteria (SC), and examination of residuals. The maximum likelihood (ML) method was applied for both pharmacokinetics and pharmacodynamics parameter estimation using ADAPT II (7).
In vivo metabolism studies. Before dosing, urine and feces were collected for 24 h as blank samples. The mice were then administered Indole 15 via the tail vein at a dose of 10 mg/kg. Urinary and fecal samples were collected at 24-h intervals for up to 72 h after IV administration. The animals were transferred to new cages at the end of each collection interval. All samples were stored at -80˚C until analysis.
Before analysis, urine samples were thawed and extracted with two volumes of ethyl acetate. The extraction procedure was repeated three times and the combined organic phase and the aqueous phase were evaporated separately to dryness. The residues were reconstituted in a mobile phase of acetonitrile/H 2 O [55:45 (v/v)], and the solution was filtered through an Acrodisc syringe filter (0.2 µm, 13 mm; Pall Corporation, East Hills, NY, USA). The filtrate was applied to liquid chromatography tandem mass spectrometry (LC-MS/MS) analyses as described below. Fecal samples were extracted three times with 10 ml of a mixture of methanol/ethyl acetate [2:1 (v/v)]. The liquid phase after each extraction was combined and evaporated. The resulting semisolid residues were then mixed with methanol and were filtered followed by LC-MS/MS analyses.
LC-MS/MS analysis.
Mass spectrometric analyses were carried out using a ThermoFinnigan LCQ DECA XP MAX ion trap mass spectrometer (San Jose, CA, USA) coupled with a Surveyor (ThermoQuest, San Jose, CA, USA) HPLC system consisting of an autosampler (SIL-20A) and an MS quaternary pump with on-line degasser. The autosampler was set at 4˚C during analysis. Data acquisition was controlled by Xcalibur software. An aliquot (10 µl) of each sample was injected into a Beckman Coulter ODS column (250x2.0 mm, 5 µm) at a flow rate of 0.2 ml/min using a gradient mobile phase comprised of water (A) and acetonitrile (B). The mobile phase was comprised of a 20% of B for the first 5 min and the flow was diverted to waste, increased to 65% of B in a linear gradient from 5 to 35 min, and then further increased to 90% of B from 35 to 50 min and maintained for 5 min, and finally returned to 20% B at 70 min. The column was equilibrated with the initial mobile phase for 10 min. The mass spectrometer was tuned with Indole 15 and operated in either positive or negative mode. The heated capillary temperature was set at 230˚C, and spray voltages were set at 3.0 and 3.5 kV for positive and negative ion mode, respectively. The sheath and auxiliary gas flow rates were 60 and 20 ml/min, respectively. For MS/MS analysis, selected precursor ions were isolated with a width of 3 m/z and fragmented with 35% energy for positive ion mode and 38% for negative ion mode.
Statistical analysis. Statistical analyses were performed using single-factor analysis of variance (ANOVA). p<0.05 was considered as a statistically significant difference.
Results

Pharmacokinetics of Indole 15 in mice.
The pharmacokinetics of Indole 15 were examined in ICR mice. A single dose (10 mg/kg) of Indole 15 via various routes of administration (IV, PO and SC) was studied in order to approximate its in vivo disposition and interpret the results of forthcoming in vivo xenograft studies.
Overall the plasma concentration profiles were fitted very well by a simultaneous two-compartment model (Fig. 3) . Plasma concentrations of Indole 15 declined rapidly after IV injection, with a terminal half-life of 2.97 h. Central volume (Vc) and clearance (CL) were estimated to be 3.67 l/kg and 4.36 l/h/ kg, respectively (Table I) . Plasma concentrations of Indole 15 peaked at about 2-3 h after SC or PO administration, with absolute bioavailability of 71.9 and 27.4%, respectively. The terminal phase after PO and SC administration prolonged as compared to that observed after an IV dose, likely reflecting a slow absorption from the PO and SC injection sites. No parent drug was detectable in either urinary or fecal samples after IV administration of Indole 15. These data, coupled with estimates of the hepatic blood flow of the mouse (5.4 l/h/kg) (8), suggest that Indole 15 was extensively metabolized in the liver with a high hepatic extraction.
Pharmacodynamic model for tumor growth in mice.
The antitumor activity of Indole 15 was evaluated in mice bearing a PC-3 xenograft over a period of 2 weeks. Compared to the vehicle control group, the tumor size at end of treatment decreased in a dose-dependent manner, with a complete inhibition of tumor growth at the highest dose (150 mg/kg) (Fig. 4) . The body weight changes among different dose cohorts at the end of treatment were not significantly different (data not shown), suggesting that Indole 15 was well tolerated in tumor-bearing mice.
Assuming that the pharmacokinetics of Indole 15 in mice did not change with dose, the PC-3 tumor growth in mice was well described by a pharmacodynamic transduction model using fixed pharmacokinetics as a driving force for drug exposure.
The initial tumor weight in each dose group was fixed as the measured mean value. Pharmacodynamic parameter estimates are presented in Table II , and demonstrate a reasonable approximation of the observed tumor growth data (Fig. 4) .
Metabolic stability of Indole 15 in mouse, rat, dog, monkey, and human liver microsomes. Metabolic stability was investigated by incubating Indole 15 with liver microsomes from mouse, rat, dog, monkey, and human. In order to evaluate the metabolism by phase II conjugation, UDPGA was introduced to the microsomal preparation. Half-life was determined with a two parameter single exponential decay curves using SigmaPlot Version 10.0 (Systat Software Inc., Chicago, IL, USA). Metabolic stability Table III . Half-life of Indole 15 in mouse, rat, dog, monkey, and human liver microsomes. Mouse  41  34  Rat  >90  >90  Dog  32  35  Monkey  22  25  Human  43  59 of Indole 15 in the presence and absence of UDPGA was not significantly different as evidenced by similar half-lives during incubation with phase I and phase I & II systems (Table III) , suggesting that glucuronidation of Indole 15 is not a predominant metabolite pathway. Indole 15 was most stable in rat liver microsomes with the longest half-life (>90 min) and degraded quickly in monkey liver microsomes with the shortest half-life (22 min) in phase I metabolism (Table III) . The phase I metabolic stability of Indole 15 in human liver microsomes (43 min) appeared to be more similar to that of mouse than the other three species (Table III) .
Identification of metabolites of Indole 15 in urine and feces.
Urinary and fecal samples were collected at 24-h intervals for up to 72 h after IV administration of Indole 15 in mice. The identification of major metabolites was based on the MS/MS data and the chromatographic retention time. Parent drug was not identified in either urine or feces, indicating that Indole 15 was extensively metabolized in mice. Fig. 5 shows the positive ion mass spectrum of the parent compound (molecular weight of 336). The corresponding [M+H] + ion (m/z 337) yielded a prominent fragment ion of 220 (Fig. 5A) , with a neutral loss of 117 Da (the mass of an indole ring). The MS 3 of the ion 220 (Fig. 5B) yielded a prominent fragment of 192 with a loss of 28 Da (Fig. 5B) , suggesting the fragment ion of 220 is most likely from the breakage of the link between indole ring B and ketone. (Table IV) .
The Other possible metabolism pathways in both positive and negative ion mode were also examined. No glucuronide conjugates or metabolites associated with the ketone reduction were identified. In summary, Indole 15 underwent extensive oxidative hydroxylation with subsequent sulfation. A possible metabolic scheme for the metabolism of Indole 15 in mice is proposed and illustrated in Fig. 7 .
Discussion
Pharmacokinetic, pharmacodynamic, and metabolism studies of Indole 15 have not been previously reported. The studies reported herein demonstrate that Indole 15 is extensively metabolized in mice with a half-life comparable to paclitaxel (9, 10) . In the in vitro metabolism study using animal liver microsomes, Indole 15 showed similar stability in human and mouse liver microsomes. Glucuronides of Indole 15 were not observed. A variety of phase I and phase II metabolites of Indole 15 were detected in the biological excreta. These metabolites indicate that Indole 15 is susceptible to two major metabolism pathways: oxidation and sulfate conjugation. Future compounds incorporating a variety of functional groups (e.g., electron donating and withdrawing groups) in the indole ring and/or the benzyl ring, may represent a reasonable approach to reduce oxidative metabolism and maintain anticancer activity, providing more metabolically stable compounds.
In order to address the mechanistic features of pharmacological systems for anticancer agents, an approach involving time-dependent transduction processes (6, 11, 12 ) is often applied to describe tumor growth kinetics. The threshold concentration for tumor eradication (C T ) was described as the drug concentration required to fully inhibit tumor growth (4). When first-order tumor growth is assumed, C T is then defined as the ratio of two rate constants, the growth rate over the killing rate (kg/k). The sulforhodamine B (SRB) assay was used to assay cell growth inhibition by Indole 15 in vitro using PC-3 cells. The concentration-cell growth profile was well described by a sigmoid model using nonlinear least squares method with the procedure PROC NLIN (SAS version 9.1, ASA Institute, Cary, NC, USA). About 10% of PC-3 cells remained alive at very high concentrations of Indole 15 (Fig. 8) , although the IC 50 was relatively small (75.3 nM) (Table V) . Based on the parameters estimated in the transduction model, C T (the ratio of kg/k) is calculated as 0.94 µg/ml (equivalent to 2.8 µM), a value consistent with the in vitro cell cytotoxicity study. Simulations based on the developed pharmacokinetic and pharmacodynamic model were further conducted to predict PC-3 tumor growth under different dosing regimens, i.e., BID vs. QD at different doses. The results suggest that the percentage of tumor reduction is only dependent on Indole 15 dose level, regardless of the dosing regimens (data not shown). Therefore, our late studies with Indole 15 focused on strategies to identify the lowest effective dose, improve oral bioavailability and reduce toxicity. Overall, these studies provided a mechanistic understanding of the factors governing the in vivo anticancer activity of Indole 15 and served as the foundation for subsequent studies showing that Indole 15 is a member of a new class of orally bioavailable tubulin antagonists.
